High Deployment: Also Trending with Balloon Expandable Valves

Conventional implantation of balloon expandable SAPIEN-3 results in a final 70:30 or 80:20 ratio of the valve in the aorta/left ventricular outflow tract.

El implante alto también es tendencia para la válvula balón expandible

This comes with permanent pacemaker implantation rates of approximately 10%. Higher deployment might translate into lower rates of conduction abnormalities and pacemaker implantation.  

The study compared a cohort of 1028 consecutive patients; 406 of these patients (39.5) received high deployment vs. conventional deployment.  

Mean implantation depth under the noncoronary cusp was significantly smaller with high deployment vs conventional technique (1.5±1.6 versus 3.2±1.9 mm; P<0.001). 

Implantation was 100% successful with both techniques. There were no cases of conversion to open heart surgery, second valve implantation within the first transcatheter aortic valve replacement, or coronary occlusion. Only one patient (0.2%) presented embolization with high deployment. 

The need for pacemaker implantation 30 days after procedure was significantly lower high deployment (5.5% vs 13.1%; p<0.001), as were rates of complete heart block (3.5% versus 11.2%; P<0.001) and new onset left bundle branch block (5.3% versus 12.2%; P<0.001).


Read also: Should Total Occlusion Influence on Revascularization Strategy?


There were no differences in mild leak (16.5% vs 15.9%; p=0.804) or moderate to severe leak (1% vs 2.7%; p=0.081) at one-year followup. 

Doppler velocity index was similar in both groups, but the high deployment technique showed slightly higher 1-year mean gradients and peak gradients.

Conclusion

High deployment of self-expandable SAPIEN-3 valves significantly reduces conduction abnormalities and pacemaker implantation rates without compromising safety. 

Original Title: Systematic Approach to High Implantation of SAPIEN-3 Valve Achieves a Lower Rate of Conduction Abnormalities Including Pacemaker Implantation.

Reference: Yasser Sammour et al. Circ Cardiovasc Interv. 2021 Jan;14(1):e009407. DOI: 10.1161/CIRCINTERVENTIONS.120.009407.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...